<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03160261</url>
  </required_header>
  <id_info>
    <org_study_id>Ex17</org_study_id>
    <nct_id>NCT03160261</nct_id>
  </id_info>
  <brief_title>Effect of Exenatide on Cortisol Secretion</brief_title>
  <official_title>Effect of Exenatide on Cortisol Secretion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tartu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Tartu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the study is to describe the effect of single dose of 10 micrograms (μg)
      exenatide given subcutaneously (s/c) on cortisol secretion. Secondary outcomes involve ACTH
      and glucose levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Exenatide is a short-acting Glucagon-Like Peptide receptor 1 (GLP-1 R) agonist.

      The clinical trial is conducted in10 healthy volunteers. Each subject receives one dose of
      subcutaneous exenatide (10 μg). After that, hormonal and physiological changes are measured
      during two hours. The blood samples are taken in 30-minute intervals.

      The primary endpoint is peak value of cortisol achieved during the 2 hours after drug
      administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 7, 2017</start_date>
  <completion_date type="Actual">December 28, 2017</completion_date>
  <primary_completion_date type="Actual">December 28, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single-group, open-label</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cortisol peak</measure>
    <time_frame>every 30 minutes during 2 hours after injection</time_frame>
    <description>Maximum concentration achieved after exenatide dose (any timepoint after injection)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adrenocorticotropin (ACTH) peak</measure>
    <time_frame>every 30 minutes during 2 hours after injection</time_frame>
    <description>Maximum concentration achieved after exenatide dose (any timepoint after injection)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>Glucose measured every 30 minutes during 2 hours after injection</time_frame>
    <description>Glucose values' area under the curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth hormone</measure>
    <time_frame>every 30 minutes during 2 hours after injection</time_frame>
    <description>Maximum concentration achieved after exenatide dose (any timepoint after injection)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>heart rate</measure>
    <time_frame>every 30 minutes during 2 hours after injection</time_frame>
    <description>Change in heart rate</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood pressure</measure>
    <time_frame>every 30 minutes during 2 hours after injection</time_frame>
    <description>Change in blood pressure</description>
  </other_outcome>
  <other_outcome>
    <measure>nausea</measure>
    <time_frame>every 30 minutes during 2 hours after injection</time_frame>
    <description>intensity of nausea in visual analogue scale</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Exenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection of 10 μg Exenatide subcutaneously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide Injection</intervention_name>
    <description>Single injection of Exenatide 10μg subcutaneously</description>
    <arm_group_label>Exenatide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-50 years

          -  Body weight &gt;65 kg

        Exclusion Criteria:

          -  Presence of chronic illness

          -  daily use of any medicines

          -  pregnancy, lactation

          -  use of oral contraceptives during previous 2 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vallo Volke, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tartu University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2017</study_first_submitted>
  <study_first_submitted_qc>May 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2017</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Tartu</investigator_affiliation>
    <investigator_full_name>Vallo Volke</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

